Skip to content
Screener

Operating Cash Flow at other companies

Pfizer logo
PfizerPFE
$2.62B+12.0%
Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX
-$50.35M+47.1%
AbbVie logo
AbbVieABBV
$3.83B+134%
Immunome logo
ImmunomeIMNM
-$58.64M-10.5%
Arcus Biosciences logo
Arcus BiosciencesRCUS
-$119M+10.5%
CTO
Citius Oncology, Inc.CTOR
-$3.83M-179%

Other financials

Income statement

See full
Revenue-
Gross profit-
Operating income-$9.3M-52.6%
Net income-$8.4M-44.6%
EPS (diluted)-$0.05+28.6%

Balance sheet

See full
Cash & equivalents$107.1M+277%
Total debt$871.0K+0.1%
Total equity$107.4M+287%
Total assets$114.2M+227%

Valuation

See full
Market cap$2.3B+1,350%
Enterprise value$2.19B+1,537%

Profitability

See full
Gross margin90%-7.4pp
Operating margin-4,195%-4,591pp
Net margin-4,130.1%-4,444pp
FCF margin-300.5%

Returns & leverage

See full
Return on equity-43.6%-17.9pp
Debt / equity0.0×
Current ratio17.2×+12.6×

Where this comes from

Reported directly by SELLAS Life Sciences Group, Inc. in its filing.

Tagged under the XBRL concept us-gaap:NetCashProvidedByUsedInOperatingActivities.

The source filing: SELLAS Life Sciences Group, Inc.’s 10-Q, filed May 12, 2026.

Filed
May 12, 2026, 4:01 PM EDT
Fiscal quarter
Q1 FY2026
Calendar quarter
Q1 2026
Accession
0001390478-26-000008
Line itemThree Months Ended March 31, 2026Three Months Ended March 31, 2025
Accounts payable685277
Accrued expenses and other current liabilities(1,264)(2,895)
Operating lease liabilities(159)(159)
Net cash used in operating activities(8,846)(9,070)
Cash flows from financing activities:
Proceeds from the exercise of common stock warrants44,084503
Proceeds from issuance of common stock, common stock warrants, and pre-funded warrants, net of issuance costs23,030
Proceeds from employee stock purchases6648

ITEM 1. FINANCIAL STATEMENTS

FAQ

What is SELLAS Life Sciences Group, Inc.'s operating cash flow?
SELLAS Life Sciences Group, Inc. (SLS) reported operating cash flow of -$8.85M in Q1 2026.
How has SELLAS Life Sciences Group, Inc.'s operating cash flow changed year-over-year?
SELLAS Life Sciences Group, Inc.'s operating cash flow increased by 2.5% year-over-year, from -$9.07M to -$8.85M.
What is the long-term trend for SELLAS Life Sciences Group, Inc.'s operating cash flow?
Over 4 years (2021 to 2025), SELLAS Life Sciences Group, Inc.'s operating cash flow has grown at a 2.2% compound annual growth rate (CAGR), from -$26.02M to -$28.39M.
What does operating cash flow mean?
Total cash generated by or used in core business operations — the single most important cash flow metric for assessing business health.

Ask your AI about SELLAS Life Sciences Group, Inc.'s operating cash flow.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude